Suven Life Sciences Ltd
Jyothsna Ravula has a strong background in the field of biosciences and intellectual property. Jyothsna began their career in 2003 as a Project Trainee at G.V.K. Biosciences Pvt. Ltd., where they worked on organic reaction databases and Biocuration projects. From 2004 to 2005, they were a Trainee Scientist at Jubilant Biosys, where they focused on deciphering signal transduction pathways in diseases like asthma, melanoma, and Alzheimer's disease. Since 2005, Jyothsna has been working at Suven Life Sciences Ltd. as the Chief Scientist for Intellectual Property & Regulatory. Jyothsna'sresponsibilities at Suven Life Sciences include patent drafting, filing, and prosecuting patent applications, conducting novelty searches, and providing IP strategies for research projects.
Jyothsna Ravula's education history is as follows:
- From 1997 to 2000, they attended B.G.R. Women's Academy, which is affiliated with S.V University. Jyothsna obtained a Bachelor of Science degree with a focus on Biochemistry, Chemistry, and Zoology.
- In the years 2000 to 2002, Jyothsna pursued their Master of Science degree at VEL'S college of sciences, University of Madras in Chennai. Jyothsna'sfield of study was Biotechnology.
- In 2003 to 2004, they enrolled in an intensive course on Protein Modeling and Rational Drug Design at Biocampus, GVK.
- From 2005 to 2006, Jyothsna studied at NALSAR University and completed a Post Graduate Diploma in Patent Law.
- Additionally, in 2005, they took a general course on Intellectual Property at WIPO (World Intellectual Property Organization).
Please note that no strong assumptions have been made outside of the provided information.
This person is not in any offices
Suven Life Sciences Ltd
1 followers
Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3, 4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.